Early antibody treatment, inflammation, and risk of post-COVID conditions

By sjmartinez • September 20, 2023

Gebo KA, Heath SL, Fukuta Y, Zhu X, Baksh S, Abraham AG, Habtehyimer F, Shade D, Ruff J, Ram M, Laeyendecker O, Fernandez RE, Patel EU, Baker OR, Shoham S, Cachay ER, Currier JS, Gerber JM, Meisenberg B, Forthal DN, Hammitt LL, Huaman MA, Levine A, Mosnaim GS, Patel B, Paxton JH, Raval JS, Sutcliffe CG, Anjan S, Gniadek T, Kassaye S, Blair JE, Lane K, McBee NA, Gawad AL, Das P, Klein SL, Pekosz A, Bloch EM, Hanley D, Casadevall A, Tobian AAR, Sullivan DJ; CSSC-004 Consortium. Early antibody treatment, inflammation, and risk of post-COVID conditions. mBio. 2023 Sep 19:e0061823. doi: 10.1128/mbio.00618-23. Epub ahead of print. PMID: 37724870.

Tags: chemokines, covid-19, COVID-19 serotherapy, Cytokines, Infectious Diseases, Interleukin-6, post-acute sequelae of COVID (PASC), post-COVID condition (PCC), Publications

Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study

Shields RK, Abbo LM, Ackley R, Aitken SL, Albrecht B, Babiker A, Burgoon R, Cifuentes R, Claeys KC, Curry BN, DeSear KE, Gallagher JC, Golnabi[...]

Candida albicans recovered from persistent candidemia exhibit enhanced virulence traits

Ribeiro FC, Kemmerich KK, Gonçale JC, Junqueira JC, Mannan M, Nabeela S, Colombo AL, Uppuluri P. Candida albicans recovered from persistent candidemia exhibit enhanced virulence[...]

Integration of HIV pre-exposure prophylaxis (PrEP) services for pregnant and breastfeeding women in eight primary care clinics: results of an implementation science study

Nelson A, Bheemraj K, Dean SS, de Voux A, Hlatshwayo L, Mvududu R, Berkowitz N, Neumuller C, Jacobs S, Fourie S, Coates T, Gail-Bekker L,[...]